ThirdBiotech

ThirdBio is a precision oncology company focused on developing next-generation bispecific and multi-specific antibodies to treat solid tumors. Launched in March 2024 by Third Rock Ventures with a $155 million Series A financing, the company aims to overcome the limitations of current immunotherapy by engineering antibodies that can simultaneously engage multiple targets with high precision. Led by industry veteran J. Carl Barrett, the company leverages a proprietary platform to design biologics that optimize immune system activation while minimizing off-target toxicities. ThirdBio is currently in the pre-clinical stage, building a pipeline of candidates designed to address unmet needs in various cancer indications.